跳轉至內容
Merck
全部照片(1)

重要文件

SML2091

Sigma-Aldrich

Dalcetrapib

≥97% (HPLC)

同義詞:

JTT-705, RO-4607381, S-[2-[[1-(2-ethylbutyl)cyclohexane]carbonylamino]phenyl]-2-methylpropanethioate

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C23H35NO2S
CAS號碼:
分子量::
389.59
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77
暫時無法取得訂價和供貨情況

化驗

≥97% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

CC(C)C(SC1=CC=CC=C1NC(C2(CCCCC2)CC(CC)CC)=O)=O

InChI

1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)

InChI 密鑰

YZQLWPMZQVHJED-UHFFFAOYSA-N

生化/生理作用

Cholesteryl ester transfer protein (CETP) inhibitor; increases serum levels of HDL-cholesterol
Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. It increases HDL levels, but showed variable results on clinical outcomes. Clinical outcomes, effects on C-reactive protein and cholesterol efflux have been found to be genotype-dependent, influenced by correlated polymorphisms in the ADCY9 (adenylate cyclase type 9) gene. Positive results were obtained with AA genotype of ADCY9 gene whereas the GG genotype showed negative results and the AG genotype was neutral.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Jean-Claude Tardif et al.
Arteriosclerosis, thrombosis, and vascular biology, 37(3), 396-400 (2017-01-28)
High-density lipoproteins are involved in reverse cholesterol transport and possess anti-inflammatory and antioxidative properties. Paradoxically, CETP (cholesteryl ester transfer protein) inhibitors have been shown to increase inflammation as revealed by a raised plasma level of high-sensitivity C-reactive protein. CETP inhibitors
Marie-Jeanne Bertrand et al.
Expert opinion on emerging drugs, 22(1), 1-26 (2016-12-09)
Cardiovascular (CV) atherosclerotic disease remains the leading cause of morbidity and mortality worldwide, despite the advances in contemporary therapies. Inflammation is an important process in atherosclerosis, leading to plaque rupture and acute coronary syndrome. Although statin therapy has substantially reduced

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務